Clinical Trial Update: A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial of fremanezumab for preventing episodic migraine in ages 6 to 17 has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ajovy (fremanezumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2025-04-16